Clinical Characteristics of a Patient with Mucopolysaccharidosis Type IVA (Morquio Syndrome)

Mucopolysaccharidosis (MPS) type IVA (Morquio syndrome) is a hereditary lysosomal storage disease caused by deficiency of N-acetylglucosamine-6-sulfate sulfatase. This enzyme deficiency leads to specific glycosaminoglycans (keratan sulfate and chondroitin-6sulfate) accumulation mainly in the bone and cartilage tissues, as well as in the cardiovascular, respiratory systems, and visual systems. Patients with MPS IVA look healthy at birth, however, they develop typical spine deformities (kyphoscoliosis), pectus carinatum, wrists hypermobility with decreased muscle strength and loss of fine motor skills, valgus deformation of lower limbs during the first years of life. Pathological changes in cardiovascular and respiratory systems, visual and acoustic analyzers can be revealed. Early diagnosis of the disease is crucial for timely initiation of enzyme replacement therapy. Thus, low incidence of the disease and its heterogeneous clinical picture complicates diagnosis. Consequently, patients with MAS IVA often become severely disabled as early as adolescence. Patients with severe form and without treatment die before the age of 30 due to complications of respiratory system diseases, valvular heart apparatus involvement, and cervical myelopathy.

1. Nakashima Y, Tomatsu S, Hori T, et al. Mucopolysaccharidosis IV A: Molecular cloning of the human N-acetylgalactosamine-6sulfatase gene (GALNS) and analysis of the 5-flanking region. Genomics. 1994;20(1):99–104. doi: https://doi.org/10.1006/geno.1994.1132

2. Jezela-Stanek A, Różdżyńska-Świątkowska A, Kulpanovich A, et al. Novel data on growth phenotype and causative genotypes in 29 patients with Morquio (Morquio-Brailsford) syndrome from Central-Eastern Europe. J Appl Genet. 2019;60(2):163–174. doi: https://doi.org/10.1007/s13353-019-00491-1

3. Hendriksz CJ, Harmatz P, Beck M, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110(1-2):54–64. doi: https://doi.org/10.1016/j.ymgme.2013.04.002

4. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 2015;167A(1):11–25. doi: https://doi.org/10.1002/ajmg.a.36833

5. Khan S, Alméciga-Díaz CJ, Sawamoto K, et al. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab. 2017;120(1-2): 78–95. doi: https://doi.org/10.1016/j.ymgme.2016.11.007

6. Sawamoto K, Alméciga-Díaz CJ, Mason RW, et al. Mucopolysaccharidosis type IVA: Clinical features, biochemistry, diagnosis, genetics, and treatment. In: Mucopolysaccharidoses Update. Tomatsu S, Lavery C, Giugliani R, eds. New York, NY: Nova Science Publishers; 2018. pp. 235–272.

7. Brailsford JF. Chondro-osteo-dystrophy, roentgenopgraphic & clinical features of a child with dislocation of vertebrae. Am J Surg. 1929;7:404–410.

8. Morquio L. Sur une forme de dystrophie osseuse familial. Arch Med Enfants Paris. 1929;32:129–135.

9. Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Hum Genet. 2003;123A(3): 310–313. doi: https://doi.org/10.1002/ajmg.a.20314

10. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101(3):355–358. doi: https://doi.org/10.1007/s004390050641

11. Sawamoto K, González J, Piechnik M, et al. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management. Int J Mol Sci. 2020;21(4):1517. doi: https://doi.org/10.3390/ijms21041517

12. Morrone A, Caciotti A, Atwood R, et al. Morquio A syndromeassociated mutations: A review of alterations in the GALNS gene and a new locus-specific database. Hum Mutat. 2014;35(11): 1271–1279. doi: https://doi.org/10.1002/humu.22635

13. Peracha H, Sawamoto K, Averill L, et al. Diagnosis and prognosis of Mucopolysaccharidosis IVA. Mol Genet Metab. 2018;125 (1-2):18–37. doi: https://doi.org/10.1016/j.ymgme.2018.05.004

14. Doherty C, Stapleton M, Piechnik M, et al. Effect of enzyme replacement therapy on the growth of patients with Morquio A. J Hum Genet. 2019;64(7):625–635. doi: https://doi.org/10.1038/s10038-019-0604-6

15. Do Cao J, Wiedemann A, Quinaux T, et al. 30 months followup of an early enzyme replacement therapy in a severe Morquio A patient: About one case. Mol Genet Metab Rep. 2016;9:42–45. doi: https://doi.org/10.1016/j.ymgmr.2016.10.001

16. Dhawale AA, Thacker MM, Belthur MV, et al. The Lower Extremity in Morquio Syndrome. J Pediatr Orthop. 2012;32(5):534–540. doi: https://doi.org/10.1097/BPO.0b013e318259fe57

17. Tomatsu S, Yasuda E, Patel P, et al. Morquio A syndrome: Diagnosis and current and future therapies. Pediatr Endocrinol Rev. 2014; 12 Suppl 1(0-1):141–151.

18. White KK, Jester A, Bache CE, et al. Orthopedic management of the extremities in patients with Morquio A syndrome. J Child Orthop. 2014;8(4):295–304. doi: https://doi.org/10.1007/s11832-014-0601-4

19. Tomatsu S, Averill LW, Sawamoto K, et al. Obstructive airway in Morquio A syndrome, the past, the present and the future. Mol Genet Metab. 2016;117(2):150–156. doi: https://doi.org/10.1016/j.ymgme.2015.09.007

20. Lavery C, Hendriksz C. Mortality in Patients with Morquio Syndrome A. JIMD Rep. 2015;15:59–66. doi: https://doi.org/10.1007/8904_2014_298

21. Pizarro C, Davies RR, Theroux M, et al. Surgical Reconstruction for Severe Tracheal Obstruction in Morquio A Syndrome. Ann Thorac Surg. 2016;102(4):e329–e331. doi: https://doi.org/10.1016/j.athoracsur.2016.02.113

22. Sumner J, Tomatsu S, Stapleton M, et al. Management of tracheal obstruction in MPS. In: Mucopolysaccharidoses Update. Tomatsu S, Lavery C, Giugliani R, eds. New York, NY: Nova Science Publishers; 2018. pp. 689–710,

23. Harmatz PR, Mengel E, Geberhiwot T, et al. Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study. Am J Med Genet A. 2017;173(2):375–383. doi: https://doi.org/10.1002/ajmg.a.38014

24. Leone A, Rigante D, Amato DZ, et al. Spinal involvement in mucopolysaccharidoses: a review. Childs Nerv Syst. 2015;31(2): 203–212. doi: https://doi.org/10.1007/s00381-014-2578-1

25. Nicolini F, Corradi D, Bosio S, Gherli T. Aortic valve replacement in a patient with Morquio syndrome. Heart Surg Forum. 2008;11(2): E96–E98. doi: https://doi.org/10.1532/HSF98.20071197

26. Braunlin EA, Harmatz PR, Scarpa M, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34(6):1183–1197. doi: https://doi.org/10.1007/s10545-011-9359-8

27. John RM, Hunter D, Swanton RH. Echocardiographic abnormalities in type IV mucopolysaccharidosis. Arch Dis Child. 1990; 65(70):746–749. doi: https://doi.org/10.1136/adc.65.7.746

28. Lin HY, Chuang CK, Ke YY, et al. Long-term effects of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis IVA. Pediatr Neonatol. 2019;60(3):342–343. doi: https://doi.org/10.1016/j.pedneo.2018.08.005